Advertisement
"We are very pleased to offer these new enhancements in our eClinicalsoftware," said Jim Bob Ward, Executive Vice President, Research andDevelopment, DATATRAK International. "This is a compliment to the ProductAdvisory Council; their contribution has ensured these new features andfunctionality provide a wide range of efficiencies and cost-savings for anyonewithin the clinical trial spectrum."
Advertisement
"This global market is definitely moving towards an eClinical set ofofferings for clinical trials," stated Dr. Jeffrey A. Green, President andChief Executive Officer of DATATRAK International, Inc. "Most providersattempt to piece together such a complete set of capabilities by integratingmultiple unrelated products in order to satisfy increasing client demands.The DATATRAK eClinical Platform houses all of these capabilities under oneunified database and user interface, eliminating the significant validationand logistical challenges of integration efforts from multiple providers."
DATATRAK eClinical Version 5.0 is now available. For additionalinformation please visit the company's website at www.datatrak.net or [email protected].
DATATRAK International, Inc. is a worldwide technology company focused onthe provision of multi-component eClinical solutions and related services forthe clinical trials industry. The Company delivers a complete portfolio ofsoftware products that were created in order to accelerate clinical researchdata from investigative sites to clinical trial sponsors and ultimately theFDA, faster and more efficiently than manual methods or loosely integratedtechnologies. DATATRAK's eClinical software suite can be deployed worldwidethrough an ASP offering or in a licensed Enterprise Transfer model that fullyempowers its clients. The DATATRAK software suite and its earlier versionshave successfully supported hundreds of international clinical trialsinvolving thousands of clinical research sites and encompassing tens ofthousands of patients in 59 countries. DATATRAK International, Inc.'s productsuite has been utilized in some aspect of the clinical development of 17 drugsand devices that have received regulatory approval from either the UnitedStates Food and Drug Administration or counterpart European bodies. DATATRAKInternational, Inc. has offices located in Cleveland, Ohio, Bonn, Germany, andBryan, Texas. Its common stock is listed on the NASDAQ Stock Market under theticker symbol "DATA". Visit the DATATRAK International, Inc. web site atwww.datatrak.net.
Except for the historical information contained in this press release, thestatements made in this release are forward-looking statements. Theseforward-looking statements are made based on management's expectations andbeliefs concerning future events impacting the Company and are subject touncertainties and factors (including those specified below) which aredifficult to predict and, in many instances, are beyond the control of theCompany. Factors that may cause actual results to differ materially from thosein the forward-looking statements include the limited operating history onwhich the Company's performance can be evaluated; the ability of the Companyto continue to enhance its software products to meet customer and marketneeds; fluctuations in the Company's quarterly results; the viability of theCompany's business strategy and its early stage of development; the timing ofclinical trial sponsor decisions to conduct new clinical trials or cancel ordelay ongoing trials; the Company's dependence on major customers; governmentregulation associated with clinical trials and
